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Aspergillus fumigatus, a ubiquitously distributed opportunistic
pathogen, is the global leading cause of aspergillosis and causes
one of the highest numbers of deaths among patients with fungal
infections [1]. Invasive aspergillosis is the most severe manifesta-
tion with an overall annual incidence up to 10% in immunosup-
pressed patients, whereas chronic pulmonary aspergillosis affects
about 3 million, primarily immunocompetent, individuals each
year [2]. Three triazole antifungals, namely itraconazole, vor-
iconazole, and posaconazole, are recommended first-line drugs in
the treatment and prophylaxis of aspergillosis [3]. However, azole
resistance in A. fumigatus isolates is increasingly reported with
variable prevalence in Europe, the United States, South America,
China, Japan, Iran, and India [4–9]. For example, about 10% of
strains of A. fumigatus from the Netherlands are itraconazole
resistant, and in the United Kingdom, the frequency increased
from 0%–5% during 2002–2004 to 17%–20% in 2007–2009 [10–
13]. In the ARTEMIS global surveillance program involving 62
medical centers, 5.8% of A. fumigatus strains showed elevated MICs
to one or more triazoles [5]. Similarly, the prospective SCARE
(Surveillance Collaboration on Aspergillus Resistance in Europe)
study involving 22 medical centers in 19 countries identified an
overall prevalence of 3.4% azole resistance. Azole-resistant A.
fumigatus (ARAF) ranged from 0% to 26% among the 22 centres
and was detected in 11 (57.9%) of the 19 participating European
countries [4 and P.E. Verweij, personal communication]. Inter-
estingly, almost half (48.9%) of the ARAF isolates from the
SCARE network in European countries were resistant to multiple
azoles and harbored the TR34/L98H mutation in the cyp51A gene
[4 and P.E. Verweij, personal communication]. Indeed, multi-
azole resistance in A. fumigatus due to the TR34/L98H mutations
has become an emerging problem in both Europe and Asia and
has been associated with high rates of treatment failures [12–14].
Azole antifungal drugs inhibit the ergosterol biosynthesis
pathway, specifically the cytochrome p450 sterol 14-a-demethy-
lase encoded by the cyp51A gene, which leads to depletion of
ergosterol and accumulation of toxic sterols. The majority of
ARAF isolates contain alterations in the target enzyme and the
mutated target showed reduced or no binding to the drugs [15].
While most mutations in ARAF isolates were single nucleotide
substitutions in the target gene (cyp51A), mutations at other genes
such as the cdr1B have also been reported. For example, in the
United Kingdom the frequency of ARAF isolates without cyp51A
mutations has been reported to be more than 50% [16].
Routes of Azole Resistance Development
The epidemiologic data on azole resistance is mainly from two
clinical entities. One group comprises noninvasive diseases
including patients with allergic bronchopulmonary aspergillosis
(ABPA), aspergilloma, and chronic pulmonary aspergillosis (CPA)
who were treated with long-term azole therapy (mainly itracon-
azole) and developed acquired resistance after 1–30 months of
treatment [13]. In these patients, the ARAF isolates may be
resistant to only itraconazole or exhibit a multi-azole-resistant
phenotype. The underlying resistance mechanism commonly
involves point mutations in the cyp51A gene, indicating that in
patients exposed to long-term azole therapy, the fungus is capable
of rapidly adapting to azole drug(s) [11–14]. The genotypic
analysis of serial isolates of A. fumigatus from patients with chronic
aspergillosis revealed that the initial susceptible and later resistant
isolates had the same genotype. The only changes were the specific
mutations conferring azole resistance, consistent with the devel-
opment of resistance arising from azole therapy [13].
The second group of patients with ARAF are those with acute
aspergillosis but with no known prior exposure to azole drugs [12].
In contrast to the first group in which de novo mutation of the
fungus in cavitary lesions is the primary mechanism for the
development of azole resistance, those of the second group likely
acquired ARAF strains from external environments. In fact 50%
of the patients with invasive aspergillosis due to ARAF are known
to be azole naı¨ve and the outcome of patients with azole-resistant
invasive aspergillosis has been dismal, with a mortality rate of 88%
[12]. Eighty percent of the ARAF strains from patients with
invasive aspergillosis described in the SCARE network had the
TR34/L98H mutations, which consist of a substitution of leucine
to histidine at codon 98 of the cyp51A gene in combination with a
34-bp tandem repeat in the promoter region. These mutations
enabled resistance to itraconazole and intermediate susceptibility
or resistance to voriconazole, posaconazole, or both [4,17,18]. As
described above, although the environmentally derived azole-
resistant strains are predominately associated with acute invasive
infections [12,19], the same mechanism has also been reported in
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patients with chronic and allergic pulmonary infections [20]. For
example, Denning et al. detected TR34/L98H and M220
mutations in 55.1% respiratory samples of CPA and ABPA
patients by direct PCR and some of these patients had no prior
azole therapy [20].
Environmentally Mediated Development of Azole
Resistance
Several recent findings support the hypothesis that ARAF strains
in patients with invasive aspergillosis were more likely to be
acquired from environmental sources rather than from de novo
mutation and selection within patients during azole therapy. First,
ARAF strains have been found in patients who had never been
treated with azole antifungal drugs [7,12–14]. Second, ARAF
strains have been found in many environmental niches including
flowerbeds, compost, leaves, plant seeds, soil samples of tea gardens,
paddy fields, hospital surroundings, and aerial samples of hospitals
[19,21–23]. The majority of the environmental ARAF isolates
harbor the TR34/L98H mutations at the cyp51A gene [19,21–23].
ARAF isolates with the TR34/L98H mutations have been detected
in the environment of the Netherlands, Denmark, India, and Iran
[19,21–23]. It is noteworthy that environmental surveys of ARAF
from Europe reported that 12% of Dutch soil samples and 8% of
Danish soil samples had the TR34/L98H genotype [19,22].
Similarly, environmental surveys across India detected that 7% of
all A. fumigatus isolates and 5% of soil/aerial samples carried the
TR34/L98H mutation [21]. These strains showed cross-resistance
to voriconazole, posaconazole, itraconazole, and to six triazole
fungicides used extensively in agriculture [21].
Recently, another mutation of the cyp51A gene (TR46/Y121F/
T289A) was reported in ARAF isolates from 15 patients in six
hospitals in the Netherlands [24]. Interestingly, isolates with the
same TR46/Y121F/T289A mutations were also recovered from
patients’ homes and backyards [24]. Apart from the Netherlands,
clinical and environmental strains of A. fumigatus carrying the
TR46/Y121F/T289A mutations have also been identified in
neighboring Belgium [25] and in India [26]. As most patients
acquire A. fumigatus from the environment, the emergence and
spread of azole-resistant strains in the environment will put more
humans at risk, especially those with compromised immunity.
Linking Clinical Azole Resistance in Aspergillus
fumigatus to Fungicide Usage in Agriculture
The hypothesis that clinical azole resistance in A. fumigatus is
related to the use of fungicides in agriculture was first proposed by
investigators from the Netherlands [19]. The resistant genotype
TR34/L98H was found in 90% of ARAF isolates obtained from
azole-naı¨ve patients [11] and they hypothesized that if strains of A.
fumigatus received sufficient azole challenge in the environment
through nonmedical application of azole compounds, azole-
resistant strains would be selected and spread [27]. Demethylase
inhibitors (DMIs) including azole fungicides are commonly used
for crop protection and for the preservation of a variety of
materials such as wood [27]. For example, azole fungicides are
broadly used to control mildews and rusts of grains, fruits,
vegetables, and ornamentals; powdery mildew in cereals, berry
fruits, vines, and tomatoes; and several other plant pathogenic
fungi. Over one-third of total fungicide sales are azoles (mostly
triazoles) and over 99% of the DMIs are used in agriculture. In
addition, there are over 25 types of azole DMIs for agricultural
uses, far more than the three licensed medical triazoles for the
treatment of aspergillosis. Furthermore, the azoles could persist
and remain active in many ecological niches such as agricultural
soil and aquatic environments for several months.
The widespread application of triazole fungicides and their
persistence in the environment are significant selective forces for
the emergence and spread of ARAF. These environmental
triazoles can reduce the population of azole-susceptible strains
and selecting for azole-resistant genotypes [27]. Intensive use of
DMI fungicides for post-harvest spoilage crop protection against
phytopathogenic molds is known to cause the development of
resistance in many fungi of agricultural importance. For example,
resistance or tolerance to triazole fungicides has been reported for
important crop pathogens such as Mycosphaerella graminicola (wheat),
Rhynchosporium secalis (barley), and Botrytis cinerea (strawberry) [28].
Since A. fumigatus shares its natural environments with many fungal
plant pathogens, strains of A. fumigatus are also exposed to the same
strong and persistent pressure from fungicides. Indeed, the
presence of a tandem repeat at the 59-end upstream of the 14-a-
demethylase gene is an important mechanism found in many plant
pathogenic molds resistant to sterol DMI fungicides [19].
All A. fumigatus isolates with the TR34/L98H mutations from
both clinical and environmental origins have shown cross-
resistance to not only all three medical triazoles, but also five
agricultural triazole DMI fungicides: propiconazole, bromucona-
zole, tebuconazole, epoxiconazole, and difenoconazole [21,29].
These results are consistent with the hypothesis that exposure of A.
fumigatus to azole fungicides in the environment causes cross-
resistance to medical triazoles. By molecular modeling studies,
these five triazole DMI fungicides were found to have similar
molecular structures as medical triazoles (Figure 1) and they all
adopt a similar conformation while docking the target enzyme in
susceptible strains of A. fumigatus [15,29]. However, there was
limited docking and activity against ARAF strains with the TR34/
L98H mutation [29]. A similar phenomenon was also observed in
the maize anthracnose fungus Colletotrichum graminicola. Strains of C.
graminicola were able to efficiently adapt to media containing
azoles, and those adapted to tebuconazole were less sensitive to all
tested agricultural and medical azoles than the nonadapted control
strain [28]. In addition, tebuconazole induced tandem repeat
expansion in the promoter region of cyp51A in A. fumigatus isolates
in vitro, indicating that fungicide pressure can rapidly select
adaptive genomic changes in this mold [29]. Agriculturally
selected antibiotic resistance has also been reported in many
bacteria, contributing to the broad distribution of multidrug-
resistant pathogenic bacteria in patients and hospitals. While
horizontal gene transfer is an important mechanism for the spread
of antibiotic-resistant genes among bacteria, this mechanism is not
commonly found in fungal pathogens. However, similar to that in
bacterial pathogens, once multidrug-resistant genotypes arise in
fungal pathogens, such genotypes can spread very quickly to other
geographic regions and ecological niches through vegetative cells
and airborne spores such as conidia.
Clonal Expansion and Fitness of TR34/L98H
Aspergillus fumigatus Strains
A recent analysis of 255 Dutch A. fumigatus isolates using 20
molecular markers identified five distinct genotype groups in the
Netherlands. Interestingly, all the multi-triazole resistant (MTR)
isolates with the TR34/L98H mutation belonged to one group
and, overall, they were genetically less variable than susceptible
isolates [30], consistent with a single and recent origin of the
resistant genotype. Similarly, all MTR A. fumigatus clinical and
environmental strains obtained from diverse geographical regions
from India belonged to a single multilocus microsatellite genotype
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[21]. The genotype analysis suggested that the ARAF genotype in
India was likely an extremely adaptive recombinant progeny
derived from a cross between azole-resistant strains migrated from
outside of India and a native azole-susceptible strain from within
India, followed by mutation. The abundant phylogenetic incom-
patibility is consistent with sexual mating in natural populations of
this species in India [21].
A potential consequence of harboring the multidrug-resistant
mutations in ARAF strains might be a reduced fitness in the absence
of the drug as compared to the wild-type isolates. However,
evidence so far suggested that the TR34/L98H mutation had little
or no adverse fitness consequence. For example, the composite
survival index (CSI) was used to measure the virulence properties of
the cyp51A gene–associated resistance mechanism in A. fumigatus
isolates [31]. The analyses revealed that strains with the TR34/
L98H mutation had virulence comparable to the wild-type controls
and there was no growth impairment and no reduction of virulence
with the TR34/L98H mutation [31]. A similar finding was reported
about the fitness of azole-resistant C. albicans strains with mutations
in the ERG3 gene, with the mutants retaining filamentation and
virulence properties [32]. The rapid dispersal of the ARAF strains
with the TR34/L98H genotype among regions within Asia also
supports the hypothesis that these strains have robust fitness in
natural environments, with comparable or even higher fitness than
that of wild-type strains [21,23]. However, we would like to note
that the development of azole resistance in clinical ARAF isolates
carrying mutations at other loci (i.e., the non-cyp51A gene) could
result in a reduction of virulence [33].
Perspectives
The rapid spread of ARAF strains is jeopardizing the treatment
of patients with Aspergillus diseases, ruling out the use of oral
antifungals for these patients and leaving only the option of
intravenous amphotericin B or echinocandins. Amphotericin B
has significant detrimental side-effects and echinocandins are
unable to completely kill or inhibit Aspergillus and, as such, they
have only been licensed for salvage therapy of invasive aspergil-
losis. At present, antifungal susceptibility testing of A. fumigatus
against azoles is not commonly performed and thus the overall
threat of ARAF is not yet completely known. However, it would be
beneficial to (i) have an active multi-azole susceptibility testing of
A. fumigatus to monitor the extent of the problem, (ii) reduce
agricultural use of triazole DMI fungicides, and (iii) use
combination drug therapy when dealing with infections by A.
fumigatus strains to limit the emergence of resistance. Indeed, the
European Center for Disease Prevention and Control (http://
www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC
_DispForm.aspx?ID = 1064) recommends increased surveillance for
clinical and environmental azole-resistant pathogens and to conduct
field trials to study the impact of nonmedical azole use in the
development of azole resistance in patients. A more judicious use of
azoles in patients, in agriculture settings, and alternative strategies
such as chemosensitization and/or a shift from the use of purely
chemical methods to a more integrated crop management approach
could help lower the dosage levels of fungicides in the environment
and minimize the emergence and spread of ARAF.
Although there are substantial data suggesting that agricultural
use of fungicides have driven the emergence and spread of multi-
triazole-resistant strains of A. fumigatus, conclusive evidence linking
agricultural triazole fungicides to the emergence of TR34/L98H or
TR46/Y121F/T289A genotypes in controlled field experiments is
lacking. The definite evidence will help the regulatory authorities
with formulation of policies to control the environmental-driven
azole resistance. The two major types of azole-resistant mutations
were first detected in 1998 and 2009 respectively and both are now
Figure 1. Diagrammatic representation of similar structural binding mode of medical triazoles and triazole fungicides to cyp51A of
wild-type A. fumigatus. (a) Dihalogenated phenyl group of triazoles forms van der Waals contact with the hydrophobic residues (encircled in red) of
the active site (cyp51A), and the nitrogen atom of the five-membered aromatic ring of triazoles binds to the cyp51A heme moiety. In addition, the D-
ring propionate (C2H5COO
2) of the heme moeity forms hydrogen bonds with the side-chain hydroxyl group of triazoles. (b) Triazole fungicides show
similar van der Waals contact at the hydrophobic pocket. However, the nitrogen atom of the five-membered aromatic ring of fungicide triazoles
binds to the Ser297 residue at the active site. In addition, the triazoles tebuconazole and epoxiconazole are known to interact with the His296 residue
while penconazole and metconazole form water-bridging interactions at the active site.
doi:10.1371/journal.ppat.1003633.g001
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spreading quickly (Figure 2). It is highly likely that other types of
mutations conferring multiple azole resistance could emerge in the
near future from environmental sources and spread among human
populations.
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